Zinc With Chloroquine/Hydroxychloroquine in Treatment of COVID-19

NCT ID: NCT04447534

Last Updated: 2022-04-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

191 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-06-23

Study Completion Date

2020-08-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

we want to investigate if zinc supplementation enhance the clinical efficacy of chloroquine in treatment of COVID-19.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

we want to investigate if zinc supplementation enhance the clinical efficacy of chloroquine in treatment of COVID-19. As, zinc may be of value in these cases and may be of value in enhancing chloroquine effect.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COVID

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Caregivers

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Chloroquine or hydroxychloroquine

Chloroquine or hydroxychloroquine alone

Group Type EXPERIMENTAL

Chloroquine or hydroxychloroquine

Intervention Type DRUG

Chloroquine or hydroxychloroquine

Chloroquine or hydroxychloroquine with zinc

Chloroquine or hydroxychloroquine with zinc

Group Type EXPERIMENTAL

Chloroquine or hydroxychloroquine

Intervention Type DRUG

Chloroquine or hydroxychloroquine

zinc

Intervention Type DRUG

Zinc tablets

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Chloroquine or hydroxychloroquine

Chloroquine or hydroxychloroquine

Intervention Type DRUG

zinc

Zinc tablets

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

alexoquine, chloroquine, hydroquine

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with positive COVID-19.

Exclusion Criteria

* Contraindications or hypersensitivity to chloroquine.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Tanta University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Sherief Abd-Elsalam

Ass. Prof. Tropical Medicine

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

sherief Abd-Elsalam, Ass. Prof.

Role: PRINCIPAL_INVESTIGATOR

ass. Prof. Tropical Medicine

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Tanta university hospital, Assuit University, Ainshams University

Tanta, , Egypt

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Egypt

References

Explore related publications, articles, or registry entries linked to this study.

Abd-Elsalam S, Soliman S, Esmail ES, Khalaf M, Mostafa EF, Medhat MA, Ahmed OA, El Ghafar MSA, Alboraie M, Hassany SM. Do Zinc Supplements Enhance the Clinical Efficacy of Hydroxychloroquine?: a Randomized, Multicenter Trial. Biol Trace Elem Res. 2021 Oct;199(10):3642-3646. doi: 10.1007/s12011-020-02512-1. Epub 2020 Nov 27.

Reference Type DERIVED
PMID: 33247380 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

tanta zinc chloroquine

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Efficacy of Faviprevir in COVID-19 Treatment
NCT04351295 COMPLETED PHASE2/PHASE3